Torapsel Biosimilar - Anti-LECAM3 fusion protein - Research Grade
Species
Homo sapiens
Expression system
XtenCHO
Purity
>90% by SDS-PAGE.
Buffer
0.01M PBS, pH 7.4.
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
anti-LECAM3, Leukocyte-endothelial cell adhesion molecule 3, Platelet activation dependent granule-external membrane protein, Granule membrane protein 140, GMP-140, CD62P, SELP, GRMP, PADGEM, CD62 antigen-like family member P, P-selectin, GMRP
Reference
PX-TA2037
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
Fusion - [SELPLG (selectin P ligand, selectin P glycoprotein ligand, PSGL-1, CD162) 42-89]2 - IGHG1 Fc (Fragment constant)
Description of Torapsel Biosimilar - Anti-LECAM3 fusion protein - Research Grade
Introduction
Torapsel Biosimilar is a novel fusion protein that has been developed as a potential therapeutic agent for the treatment of various diseases. This fusion protein combines the properties of an antibody and a therapeutic target, making it a promising candidate for targeted therapy. In this article, we will discuss the structure, activity, and potential applications of Torapsel Biosimilar in research settings.
Structure of Torapsel Biosimilar
Torapsel Biosimilar is a fusion protein composed of two distinct components: an antibody and a therapeutic target. The antibody component is derived from the anti-LECAM3 antibody, which specifically binds to the LECAM3 protein expressed on the surface of certain cells. The therapeutic target component is a small molecule that has been engineered to specifically target and inhibit a particular disease-related pathway.
The two components are linked together through a flexible linker, allowing for the simultaneous binding and inhibition of the targeted pathway. This unique structure of Torapsel Biosimilar makes it a highly specific and efficient therapeutic agent.
Activity of Torapsel Biosimilar
The activity of Torapsel Biosimilar is based on its dual mechanism of action. The antibody component of Torapsel Biosimilar binds to the LECAM3 protein on the surface of target cells, leading to the internalization of the fusion protein into the cell. Once inside the cell, the therapeutic target component of Torapsel Biosimilar inhibits the targeted disease-related pathway, effectively blocking its activity and preventing disease progression.
This dual mechanism of action makes Torapsel Biosimilar a highly potent and specific therapeutic agent, as it targets both the surface and internal components of diseased cells.
Applications of Torapsel Biosimilar
Torapsel Biosimilar has a wide range of potential applications in research settings. Its ability to target and inhibit specific disease-related pathways makes it a valuable tool for studying the role of these pathways in various diseases. Additionally, Torapsel Biosimilar can be used to validate the efficacy of potential therapeutic targets and to identify new targets for drug development.
Furthermore, Torapsel Biosimilar can be used in preclinical studies to evaluate its potential as a therapeutic agent for various diseases. Its dual mechanism of action and high specificity make it a promising candidate for targeted therapy in conditions such as cancer, autoimmune diseases, and inflammatory disorders.
Conclusion
Torapsel Biosimilar is a unique fusion protein that combines the properties of an antibody and a therapeutic target. Its structure and activity make it a highly specific and efficient therapeutic agent with a wide range of potential applications in research settings. Further studies and clinical trials are needed to fully understand the potential of Torapsel Biosimilar in treating various diseases, but it holds great promise as a targeted therapy option.
Reviews
There are no reviews yet.